OTLK News and Press, Outlook Therapeutics Inc.

ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it submitted a formal dispute resolution request (FDRR) to...

ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,0...

2026-03-24 07:11:45 ET More on Outlook Therapeutics Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again Biggest stock movers Tuesday: CLB, OTLK, and more Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset Seeking Alpha ...

ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,0...

2026-03-24 05:05:01 ET More on related stocks: Vertiv Holdings Co (VRT) Presents at JPMorgan Industrials Conference 2026 Transcript Vertiv: Remains A Fantastic Pick-And-Shovel AI Play Vertiv: An Upcoming S&P 500 Member, Shares Near Fair Value (Downgrade) ...

2026-03-23 17:41:12 ET More on Outlook Therapeutics Third Time's The Charm: Outlook Therapeutics' Lytenava Heads To FDA, Again Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset Seeking Alpha’s Quant Rating on Outlook Therapeutics Historic...

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has commenced a best-efforts public offering of its com...

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Cap...

ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update following its recent Type A meeting with the U.S. Food...

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in Switzerland Partnership advances European commercial ex...